TABLE 5.

Multiple-dose pharmacokinetic parameters for NFV in HIV-infected infants reported in the literature

Reference	Age and wt	Dose (mg/kg/day)	No. of subjects	Elimination half-life (h)	CL/F (liters/h/kg)	V/F (liters/kg)	M8/NFV
Rongkavilit et al. (21)	14 days	30 BID	6	3.3	1.05	5.5
		60 BID	5	4.2	1.55	10.3
		90 BID	11	5.0	1.92	13.4
	28 days	30 BID	6	4.7	1.73	10.5
		60 BID	5	4.2	1.90	14.7
		90 BID	11	4.8	2.43	18.7
Litalien et al. (13)	2.3-8.5 mo	109.4-172.4 BID or TID	14	NFV, 2.6; M8, 2.2	4.2	22.3	0.12-0.89a
Capparelli et al. (4)	15 days-2 yr	75-110 BID or TID	8		2.7		0.09b
Capparelli et al.c	0.8-21.1 yr	90 TID	7		1.87
Capparelli et al.d	≤3 mo	75 TID	5		3.2
Krogstad et al. (12)	3.6-22 mo	69 TID	19		0.8-1.8
Van Heeswijk et al. (27)	2.1-10.8 yr	90 BID or TID	12	2.5-3.1	1-1.3	3.9-6
Pai and Nahata (16)	2-7 yr	60 TID	8		1.25
	7-13 yr	60 TID	7		2.08
Floren et al. (7)	0.6-7 yr	90 TID	9		2.4		0.13-0.71a
	7.2-16 yr	90 TID	11		0.9
	3.4-11 yr	110 BID	6		1.2
Bergshoeff et al. (3)	<2 yr	87 TID	7		2.8		0.31a
	≥2 yr	84 TID	17		1.9		0.29a
Schuster et al. (22)	2-14 yr		18
	<25 kg	90-111 TID	8		1.72
		90-110 BID			1.54
	>25 kg	≤90 TID	10		≤2.30
		≤100 BID			≤1.47
This study	1.5-16.2 mo	81-203 BID and TID	18	NFV, 4.3; M8, 2.04	2.13	12.3	0.1-0.96a,e
							0.64b

^aArea under the concentration-time curve ratio.

^bConcentration ratio.

^cAbstr. 7th Conf. Retrovir. Opportunistic Infect., 2000.

^d40th ICAAC.

^eComputed from 19 kinetic values by a simple noncompartmental approach between two drug administrations.